Hypersensitive Detection and Quantitation of BoNT/A by IgY Antibody against Substrate Linear-Peptide

Tao Li, Hao Liu, Kun Cai, Maoren Tian, Qin Wang, Jing Shi, Xiang Gao, Hui Wang*

State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Fengtai District, Beijing, PR China

Abstract

Botulinum neurotoxin A (BoNT/A), the most acutely poisonous substance to humans known, cleave its SNAP-25 substrate with high specificity. Based on the endopeptidase activity, different methods have been developed to detect BoNT/A, but most lack ideal reproducibility or sensitivity, or suffer from long-term or unwanted interferences. In this study, we developed a simple method to detect and quantitate trace amounts of botulinum neurotoxin A using the IgY antibody against a linear-peptide substrate. The effects of reaction buffer, time, and temperature were analyzed and optimized. When the optimized assay was used to detect BoNT/A, the limit of detection of the assay was 0.01 mouse LD50 (0.04 pg), and the limit of quantitation was 0.12 mouse LD50/ml (0.48 pg). The findings also showed favorable specificity of detecting BoNT/A. When used to detect BoNT/A in milk or human serum, the proposed assay exhibited good quantitative accuracy (88% < recovery < 111%; inter- and intra-assay CVs < 18%). This method of detection took less than 3 h to complete, indicating that it can be a valuable method of detecting BoNT/A in food or clinical diagnosis.

Introduction

Botulinum neurotoxin (BoNT), the most acutely toxic substance to humans known, is produced by Clostridium botulinum under anaerobic conditions [1,2]. Seven types or serotypes (A to G) of botulinum toxin are currently known. Each serotype is composed of a heavy and a light chain linked by disulfide bonds [3,4]. The heavy chain is responsible for binding to specific pre-synaptic neuronal cell receptors and facilitating internalization. The light chain is a zinc-dependent endopeptidase that specifically cleaves soluble SNAP proteins essential for docking and fusion neurotransmitters containing vesicles at the nerve terminal. Types A, E, and C1 toxins cleave SNAP251-206 (synaptosomal associated protein with 25 kDa molecular mass) at the Q197–R198, R180–I181, and R198–A199 positions [5]. Types B, D, F, and G toxins cleave vesicle-associated membrane protein (VAMP) at the Q76–I181, and R198–A199 positions [5]. Types C1 toxin is known to also cleave Syntaxin.

Botulinum neurotoxins type A (BoNT/A) is the most toxic serotype to human. The 50% lethal dose (LD50) of BoNT/A to humans is only 0.1–1 ng/kg [2]. Given its small intoxicating dose, short eclipse period, and simple production, BoNT/A is a potential bioterrorism agent. Thus, BoNT/A has become a research hotspot in medical shielding research in recent years. If botulism diagnosis is promptly made, a proper therapy method can be applied and significantly decrease fatality. Therefore, a swift, precise assay for botulinum neurotoxin analysis is important for BoNT prevention and cure.

The mouse bioassay has been the standard for testing BoNT-containing samples for the past 30 years [7–9]. However, this assay is time consuming, requires the use of many animals, and has poor repeatability because of numerous fluctuant parameters involved. Several in vitro assays have also been reported for the detection of BoNT/A, relying either on mass spectrometry [10–12], immunological detection [13–15], Förster resonance energy transfer (FRET) [16–18], or endopeptidase activity [19–27]. The advantage of the endopeptidase assay is that it measures and quantitates the L-chain activity of the toxin, which is directly responsible for neurotransmission inhibition. However, many of these methods require a multi-step procedure or suffer from high variability, low sensitivity, or long reaction time.

The residues of the substrate SNAP25 at cleavage sites, which are normally buried in a helix, are exposed after BoNT cleavage, making the substrate become a linear peptide. Using the IgY antibody against this linear-peptide substrate, we improved a previous endopeptidase assay and developed a simple method for the detection and quantitation of BoNT/A. This method can be expanded to detect other types of botulinum toxins or specific enzymes in the future.

Materials and Methods

Bacterial strains, plasmids, and media

C. botulinum type A expression vectors pET32a (+) and pET22b (+) were from in our laboratory. Escherichia coli BL21 (DE3), E. coli DH5α, and pMD18-T cloning vectors were purchased from Beijing TransGen Biotech (China). Taq DNA polymerase, T4 DNA ligase, and restriction endonucleases were obtained from New England Biolabs (Beijing, China). PCR primers were synthesized by Beijing Sunbio Tech Co. Ltd. Plasmid mini-kits and gel extraction kits were from Beijing Biomed Co. Ltd.

* E-mail: geno0109@vip.sina.com
Hypersensitive Detection of BoNT/A

Production and identification of BoNT/A and BoNT/E

The bacteria strain used for production of BoNT/A and BoNT/E were *C. botulinum* strain 230611 and 230612 which were isolated from cases of food-borne botulism in China. *C. botulinum* strain 230611 and 230612 was grown at 37 °C (30°C) in TPGY medium. After 48 h of incubation, the culture was processed for toxin purification using a previously described method [28], with modifications. The extracted toxins serially diluted with sodium phosphate buffer were assayed for toxicity by intraperitoneal injection into groups of 10 BALB/c mice (Laboratory Animal Center, Beijing, China). The concentration that killed half of the animals within 7 days was considered as the LD50. The extracted BoNT/A was mixed with a half-volume of enzyme reaction buffer (50 mM HEPES, 2 mM DTT, 10 μM ZnCl2, pH 7.5) and incubated at 37 °C for 15 min. Purified SNAP25 proteins were then added, and the mixture was incubated at 37 °C for 1 h. The endopeptidase reaction was analyzed by SDS-PAGE.

Optimization of reaction buffer of the endopeptidase assay

To determine the optimized condition of the endopeptidase assay, an ALc endopeptidase assay was performed on a SNAP25-coated plate with three different reaction buffers. First was Ni-NTA buffer (pH 7.4), containing 0.02 M Na3PO4, 0.5 M NaCl, and 0.4 M imidazole. Second was PBS buffer (pH 7.2), containing 0.006 M Na3PO4, 0.002 M Na2HPO4, and 0.14 M NaCl. Third was PB buffer (pH 7.2), containing 0.009 M Na3PO4 and 0.002 M Na2HPO4.

The purified recombinant proteins (ALc and SNAP25) in B buffer were dialyzed to PBS and PB buffers at 4 °C for 24 h. Plates were coated with SNAP25 in three buffers (PBS buffer, B buffer, and H2O) at 0.4 μg/well, and incubated overnight at 4 °C. The plates were washed three times at 3 min intervals with PBST, and then blocked with BSA at 37 °C for 2 h. The ALc proteins in the three buffers (PBS, PB, and B buffers) were mixed with a half-volume of reaction buffer (50 mM HEPES, 2 mM DTT, 10 μM ZnCl2, pH 7.5). Then, serially diluted mixtures were added (100 μL/well), maintaining the temperature at 37 °C for 1 h. The samples were washed, and anti-subA IgY was added at 200 μL/well and incubated at 37 °C for 1 h. The samples were rewashed and horseradish-peroxidase conjugated rabbit anti-hen secondary antibody (Sigma Chemical Co.) was added and incubated at 37 °C for 0.5 h. Then, AB buffer was added and the mixture was incubated for 10 min. The reaction was stopped with 2 M H2SO4. The result was read at 450 nm using an absorbance microplate reader. A reading two times higher than that of the negative control was regarded as positive.

Optimization of reaction temperature and time of the endopeptidase assay

To determine the optimum reaction temperature and time of the ALc endopeptidase assay, gradient-diluted ALc was added to a SNAP25 coated plate and incubated at two reaction temperatures (37 °C and RT) for three reaction times (1, 2, and 4 h) with an optimized reaction buffer combination, and then tested by ELISA. The result was read at 450 nm using an absorbance microplate reader. A reading two times higher than that of the negative control was regarded as positive.

Detection and quantitation of BoNT/A and BoNT/E standard protein using IgY antibody

To determine sensitivity and specificity, serially diluted BoNT/A and BoNT/E proteins were added to a SNAP25 coated plate,
incubated under the optimized condition, and tested by ELISA for parallel line analysis. The limit of detection (LOD) and limit of quantitation (LOQ) of the method were detected by BoNT/A. The specificity of the method was verified by BoNT/E.

A standard curve was constructed by plotting the absorbance values (mean of triplicate wells) against standard toxin concentrations. Unknown concentrations were determined from the linear regression equation.

Calculation of method precision by testing BoNT/A mixed with milk and human serum

Three BoNT/A concentrations (0.24 LD_{50}, 0.32 LD_{50}, and 0.48 LD_{50}) were mixed with reaction buffer, milk, or human serum, and then detected using IgY antibody. The ELISA result was read at 450 nm by an absorbance microplate reader. Intra- and inter-assay precisions were analyzed by BoNT/A incorporated in milk and human serum.

Statistical analysis

The results are presented as the mean ± standard error (SE). Statistical significance was determined by Student’s t test or the chi-squared test. P values <0.05 were considered significant.

Results

Expression and characterization of SNAP25 and BoNT/ALc

The expression and purity of SNAP25 and ALc were verified by SDS-PAGE and visualized by Coomassie blue staining and Western blot analysis using mouse anti-His-tag antibody and horse anti-BoNT/A antibody. The purity of the obtained proteins was verified as 85% by one-step Ni-column purification analyzed by the Bandscan 5.0 software. The molecular weights of the proteins matched the theoretically predicted ones, i.e., 28 and 60 kDa (Figs. 1A and 1B). The final yields of purified SNAP25 and ALc were 7.76 and 30.01 mg/L culture. Purified ALc protein was used to cleave recombinant SNAP25. The result indicated that recombinant ALc had an endopeptidase toward SNAP25 and presented linear concentration–response relations (Fig. 1C).

The LD_{50} of the extracted BoNT/A was calculated about 4 pg/mouse based on the result of the sequentially diluted BoNT/A intraperitoneal injection to mice. The protein activity of SNAP25 mixed with ALc. M: marker; 1: 10^{5} l of ALc; 2: 10^{5} l of SNAP25; 3: 10^{5} l of SNAP25 + 5 \mu l of ALc; 4: 10^{5} l of SNAP25 + 15 \mu l of ALc; 5: 10^{5} l of SNAP25 + 20 \mu l of ALc.

Effects of buffer, time, and temperature on the endopeptidase assay

To determine the optimum conditions for the endopeptidase assay, the effects of buffer, time, and temperature were examined. First, the endopeptidase assay was performed with nine buffer combinations, namely, three SNAP25 buffers (PBS, B buffer, and H_{2}O) with three ALc buffers (PBS, PB, and B buffers). To examine the dose–effect relationship of the endopeptidase assay of ALc in different buffers, gradient-diluted ALc was added to SNAP25 coated plates. The result of the endopeptidase assay was analyzed by ELISA and expressed in terms of the mean OD_{450} (Fig. 3A).

Figure 1. SDS-PAGE results of purified SNAP25 and ALc, as well as cleaved SNAP25 by BoNT/A and ALc. A) SDS-PAGE result of purified SNAP25. M: marker; 1: purified SNAP25. B) SDS-PAGE result of purified ALc. M: marker; 1: purified ALc. C) SDS-PAGE result of purified SNAP25 mixed with ALc. M: marker; 1: 10 \mu l of SNAP25; 2: 10 \mu l of SNAP25 + 5 \mu l of ALc; 3: 10 \mu l of SNAP25 + 10 \mu l of ALc; 4: 10 \mu l of SNAP25 + 15 \mu l of ALc; 5: 10 \mu l of SNAP25 + 20 \mu l of ALc.

doI:10.1371/journal.pone.0058908.g001

Sensitivity was calculated based on the average background values added to two times the standard deviation (2SD). The results showed that the sensitivity of the analysis system was the highest (p < 0.01, Fig. 3B) with SNAP25 in B buffer and ALc in PBS buffer. Thus, this buffer combination was used throughout the assay.

The endopeptidase assay was also performed with different time and temperature combinations, which also showed linear concen-
tration–response relations (Fig. 4A and Table S2). Based on the same analysis as that on buffer effect, we found that the sensitivity of the endopeptidase assay at 37 °C was better than that at RT (25 °C; *p < 0.01) (Fig. 4B). Whether this result reflected the thermal conformational stability of ALc and SNAP25 was unclear. However, the reaction time from 1 h to 4 h did not affect the assay (Fig. 4B).

Therefore, the assay with SNAP25 in B buffer and ALc in PBS buffer at 37 °C for 1 h was the optimum condition of the endopeptidase assay and was thus used in subsequent experiments.

### 3.4 LOD and LOQ for BoNT/A of the method

The endopeptidase assay was used under optimized conditions to detect BoNT/A standard preparation. The results (Table 1 and Fig. 5) showed that the OD_{450} reads and the concentration of BoNT after log conversions presented linear concentration–response relations. The correlation coefficient reached 0.99, and the calculated equation concentration–response relations were used to compute the BoNT/A concentration in the test sample.

The background mean added to twice the standard deviation gave the LOD of the endopeptidase assay [24], which was 0.01 mouse LD_{50} (0.04 pg BoNT/A). Based on CV < 16%, the LOQ was 0.12 mouse LD_{50} (0.48 pg BoNT/A).

The relationship between the detection results of BoNT/A standard preparation and purified ALc was analyzed (*p < 0.01*). The result proved that ALc can be used as control instead of BoNT/A during the development and application of the method.

### Specificity of the method

The specificity of the method was determined by analyzing the result of gradient diluted BoNT/E incubated with coated SNAP25 and compared with BoNT/A. In contrast to BoNT/A, the BoNT/E concentration and the OD_{450} reads did not present a concentration–response relation (Fig. 5). No positive reading was obtained even though the BoNT/E concentration reached 15.36 LD_{50}, indicating that the specificity of the assay was good.

### Table 1. Detection of BoNT/A with different concentration by anti-subA IgY.

| Concentration of BoNT/A (LD_{50}) | OD_{450} | Mean OD_{450} | SD | CV (%) |
|-----------------------------------|----------|---------------|----|--------|
| 0                                 | 0.022    | 0.027         | 0.026 | 0.004 | 15.35 |
| 0.015                             | 0.038    | 0.04          | 0.036 | 0.006 | 16.43 |
| 0.03                              | 0.043    | 0.063         | 0.054 | 0.01  | 18.79 |
| 0.06                              | 0.06     | 0.072         | 0.072 | 0.012 | 16.05 |
| 0.12                              | 0.108    | 0.115         | 0.117 | 0.01  | 8.24  |
| 0.24                              | 0.123    | 0.127         | 0.131 | 0.011 | 8.49  |
| 0.48                              | 0.153    | 0.162         | 0.145 | 0.023 | 15.68 |
| 0.96                              | 0.218    | 0.237         | 0.222 | 0.014 | 6.26  |
| 1.92                              | 0.272    | 0.266         | 0.278 | 0.015 | 5.51  |
| 7.68                              | 0.401    | 0.542         | 0.482 | 0.073 | 15.13 |
| 15.36                             | 0.627    | 0.697         | 0.675 | 0.041 | 6.12  |

* doi:10.1371/journal.pone.0058908.t001
Figure 3. Effects of buffer in the ALc endopeptidase assay. A) The concentration–response relations between OD_{450} and ALc with different buffer combinations. B buffer: 0.02 M Na_3PO_4, 0.5 M NaCl, 0.4 M imidazole, pH 7.4; PBS buffer: 0.008 M NaH_2PO_4, 0.002 M Na_2HPO_4, 0.145 M NaCl, pH 7.2; PB buffer: 0.008 M d NaH_2PO_4, 0.002 M Na_2HPO_4, pH 7.2. B) Sensitivity of endopeptidase assay in different buffer combinations.

doi:10.1371/journal.pone.0058908.g003
Figure 4. Effects of temperature and time in the ALc endopeptidase assay. A) Concentration–response relations between OD_{450} and ALc with different reaction temperatures and time combinations. B) Sensitivity of the endopeptidase assay at different temperature and time combinations.

doi:10.1371/journal.pone.0058908.g004
Detection of BoNT/A in milk or serum samples and calculation of the method precision

BoNT/A with three different concentrations (0.24 mouse LD50, 0.32 mouse LD50, and 0.48 mouse LD50) in reaction buffer, milk, or human serum samples were detected using the proposed method. The BoNT/A concentration in the different samples were calculated (Table 2). Then, the calculated recoveries as well as the intra- and inter-assay precisions were analyzed. The results indicated that the method had good accuracy and precision (88% < recovery < 111%; inter- and intra-assay CVs < 18%).

Discussion

The mouse bioassay has been the standard for testing BoNT-containing samples for the past 30 years. However, this assay is time consuming, requires the use of many animals, and has poor repeatability. In recent years, the IgY antibodies produced in hens have been proven useful in many applications, including immunotherapy and immunodiagnostics [29,30]. In the present study, we investigated the ability of IgY to detect and quantitate BoNT/A. First, we synthesized peptide subA:NKTRIDAEAO located N-terminal 10 a.a. from cleavage site of BoNT/A at SNAP25. Then, we used it as an antigen to immunize the leghorn hens. Finally, IgY antibody was prepared by the water dilution method and purified with an IgY purification HiTrap column. The entire process of IgY antibody production was simple and convenient. Moreover, given that the antibodies were harvested from eggs, bleeding the animal was unnecessary. Therefore, this method of IgY production in hens favored animal welfare. The availability of a large amount of IgY from egg yolks makes it feasible to use as an antibody in toxin detection. The titer and specificity of IgY were confirmed by ELISA. Our data showed that the IgY titer steadily increased with increased booster vaccination. The anti-subA IgY titer reached 320 000 after four vaccinations, and remained stable for 1 year.

Several endopeptidase assays utilizing antibodies to 5, 7, or 8 a.a. of the exposed SNAP25 cleavage site have been developed [19–24]. However, these assays lack ideal reproducibility or sensitivity (0.13 ng/ml and 0.1–0.8 mouse LD50/ml, respectively) or suffer from the unwanted effects of albumin [19–23]. Jones et al. [24] developed an endopeptidase immunoassay with high sensitivity (0.01 LD50/ml), but it required more than 18 h to finish. In the current study, many changes were made to previous techniques to remove the step that may introduce errors into the assay, as well as to optimize the reaction condition and improve the sensitivity.

### Table 2. Detection of BoNT/A in reaction buffer, milk, or serum samples.

| Sample | Concentration of BoNT/A (LD50) | Calculated concentration of BoNT/A (LD50) | Intra-M (LD50) | Intra-SD (LD50) | Intra-CV (%) | Recovery (%) | Inter-M (LD50) | Inter-SD (LD50) | Inter-CV (%) | Recovery (%) |
|--------|--------------------------------|------------------------------------------|---------------|----------------|--------------|-------------|---------------|----------------|--------------|-------------|
| B      | 0.24                           | 0.265                                    | 0.2307        | 0.027          | 11.3         | 99.9        | 0.2511        | 0.0344         | 13.70        | 99.9        |
| M      | 0.24                           | 0.2505                                   | 0.2307        | 0.027          | 11.3         | 99.9        | 0.2511        | 0.0344         | 13.70        | 99.9        |
| S      | 0.24                           | 0.2455                                   | 0.2307        | 0.027          | 11.3         | 99.9        | 0.2511        | 0.0344         | 13.70        | 99.9        |
| B      | 0.32                           | 0.3675                                   | 0.3198        | 0.0313         | 10.4         | 94.3        | 0.3156        | 0.0324         | 10.30        | 94.3        |
| M      | 0.32                           | 0.3198                                   | 0.3198        | 0.0313         | 10.4         | 94.3        | 0.3156        | 0.0324         | 10.30        | 94.3        |
| S      | 0.32                           | 0.3372                                   | 0.3198        | 0.0313         | 10.4         | 94.3        | 0.3156        | 0.0324         | 10.30        | 94.3        |
| B      | 0.48                           | 0.4536                                   | 0.4536        | 0.0439         | 9.1          | 89.8        | 0.4291        | 0.0499         | 11.60        | 89.8        |
| M      | 0.48                           | 0.4823                                   | 0.4823        | 0.0439         | 9.1          | 89.8        | 0.4291        | 0.0499         | 11.60        | 89.8        |
| S      | 0.48                           | 0.48                          | 0.4823        | 0.0439         | 9.1          | 89.8        | 0.4291        | 0.0499         | 11.60        | 89.8        |

Sample B, M, S: BoNT/A mixed with reaction buffer, milk, or human blood. Intra-M, Intra-SD, Intra-CV: the mean, standard deviation and coefficient of variability of calculated concentration of BoNT/A with same sample. Inter-M, Inter-SD, Inter-CV: the mean, standard deviation and coefficient of variability of calculated concentration of BoNT/A with different samples.
Full-length SNAP25 was recombiantly expressed and used as a substrate in this endopeptidase assay, different from previous reports using only part of the sequence of SNAP25 [10,16,17,22]. The formation of natural conformation was easier than the formation of a partial sequence, which helped improve the sensitivity of the endopeptidase assay. The recombinant SNAP25 contained BoNT/A, BoNT/E, and BoNT/C1 cleaved sites; thus, it can further be used to detect BoNT/E and BoNT/C1. Different from other methods of BoNT/A detection [17–24], recombinant ALc instead of BoNT/A was used as a positive control in the immunoassay. This method can avoid operator exposure to BoNT/A, and remarkably eliminate the effect of BoNT/A purity.

BoNT/A and ALc have different activities under different conditions [17,24]. The reaction conditions in the current study were optimized to obtain better sensitivity. The results showed that the activities of SNAP25 and ALc varied with each buffer. In the Ni-NTA elution (B buffer) and PBS buffers, SNAP25 exhibited significantly higher activity than in ddH2O. In ddH2O, the residues at the cleavage sites may be more easily exposed without BoNT/A or ALc cleavage, which led to a higher background value and influenced the sensitivity. The study also showed that ALc had different stabilities with different buffers. Precipitation of ALc occurred in B buffer after storage at −20 °C, whereas ALc was relatively stable in PBS buffer. Finally, the sensitivity with optimized buffer was 7.3-fold higher than with SNAP25 in ddH2O and ALc in PB buffer. The results of reaction temperature optimization experiment showed that the sensitivity was higher at 37 °C than at RT. This result revealed that ALc had higher activity at 37 °C, consistent with previous reports on BoNT/A [17,24]. However, the sensitivity of this method can also reach 0.1 pg at RT, indicating good temperature compatibility. The results of reaction time effect experiments showed that the method can achieve increased sensitivity with increased reaction time. However, the difference in sensitivity from 4 h to 1 h was not significant at 37 °C; thus, 1 h was chosen as the optimum response time. The ability of the proposed method to detect BoNT/A in food or blood was investigated and analyzed. The proposed method also showed good quantitative accuracy (88% < recovery < 111%, inter- and intra-assay CVs < 18%) when used to detect and quantify trace amounts of BoNT/A (0.24 mouse LD50) in milk or human serum. This result indicated that the complex ingredients of human serum or milk had little interference to the method. The accuracy of quantitation may further improve when the samples are pretreated, such as by concentration and desalination. According to previous reports [2], the LD50 of BoNT/A to humans is 0.1–1 ng/kg. Thus, 6 ng of BoNT/A may be lethal to an adult weighing 60 kg. The LOD of the proposed method was 0.01 mouse LD50 (0.04 pg). Therefore, the sensitivity of this method was sufficient for the practical diagnosis of a patient. The method also only needed less than 3 h and did not rely on special equipment when the substrate (SNAP25) was coated in the well in advance, making it easy to use in clinical diagnosis.

In summary, a simple and rapid method of BoNT/A detection and quantitation was developed using anti-subA IgY antibody. High sensitivity (LOD = 0.01 mouse LD50 and LOQ = 0.12 mouse LD50) was obtained by optimizing the reaction substrate and conditions. Favorable specificity and anti-interference activity were achieved through BoNT/E and complex sample detection experiment. Therefore, the proposed method can be a valuable method of BoNT/A detection in food or for clinical diagnosis.

Supporting Information

Table S1 the concentration-response relations between OD450 and ALc with different buffer combination. (DOC)

Table S2 the concentration-response relations between OD450 and ALc with different reaction time and temperature combination. (DOC)

Author Contributions

Conceived and designed the experiments: TL, HW. Performed the experiments: TL, HL, KC, QW, JS. Analyzed the data: TL, HL, MT, XG. Wrote the paper: TL, HW.

References

1. Peck MW (2009) Biology and genomic analysis of Clostridium botulinum. Adv Microb Physiol 55: 183–265, 320.
2. Johnson EA, Bradshaw M (2001) Clostridium botulinum and its neurotoxins: A metabolic and cellular perspective. Toxicon 39: 1709–1722.
3. Montecucco C, Schiavo G (1994) Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol 13: 129.
4. Ongena F, Nageswaran A, Koh Y, Nair S, Wu X, et al. (2010) Comparison of sensitivities of commercially available and in-house botulinum neurotoxin immunoassays. J. Immunol. Methods 353: 248–256.
5. Kim Y, Kim J, Lee E, Kang I, Kim S, et al. (2012) Detection of botulinum neurotoxin type A in food by using high-throughput FRET-assay. J Pharmacol Toxicol Methods 65(1):8–12.
6. Hallis B, James BA, Shone CC (1996) Development of novel assays for Clostridium botulinum type A toxin in therapeutic preparations. J. Immunol. Methods 189: 181–191.
7. Liu J, Song C, Li Y, Liu F, Zhang K, et al. (2012) Development of highly sensitive chemiluminescence enzyme immunoassay based on the anti-recombinant F subunit of botulinum neurotoxin type A monoclonal antibodies. Natl Acad Sci USA, 101(41):14701–4704.
8. Joshi SG (2012) Detection of biologically active botulinum neurotoxin--A in serum using high-throughput FRET-assay. J Pharmacol Toxicol Methods 65(1):8–12.
9. Hallis B, James BA, Shone CC (1996) Development of novel assays for Clostridium botulinum type A and B neurotoxins based on their endopeptidase activities. J. Immunol. Methods 180: 181–191.
10. Rivera VR, Gamez FJ, Keener WK, White JA, Poli MA (2006) Rapid detection of Clostridium botulinum toxins A, B, E, and F in clinical samples using high-throughput FRET-assay. J. Immunol. Methods 315:23–30.
11. Jackson J, Jackson A, Jackson D, et al. (2012) Development of highly sensitive chemiluminescence enzyme immunoassay based on the anti-recombinant H(C) subunit of botulinum neurotoxin type A monoclonal antibodies. Anal Chem Acta. 735:23–30.
12. Schantz EJ, Kautter DA (1978) Microbiological methods: standardized assay for Clostridium botulinum and its toxins. A metabolic and cellular perspective. Toxicon 39: 1709–1722.
13. Ekong TA, K McLellan, D Sarsfield (1995) Immunological detection of Clostridium botulinum toxin type A in therapeutic preparations. J. Immunol. Methods 180: 181–191.
14. Liu J, Song C, Li Y, Liu F, Zhang K, et al. (2012) Development of highly sensitive chemiluminescence enzyme immunoassay based on the anti-recombinant H(C) subunit of botulinum neurotoxin type A monoclonal antibodies. Anal Chem Acta. 735:23–30.
15. Rivera VR, Gamez FJ, Keener WK, White JA, Poli MA (2006) Rapid detection of Clostridium botulinum toxins A, B, E, and F in clinical samples using high-throughput FRET-assay. J. Immunol. Methods 315:23–30.
16. Dong H, Tepp WH, Johnson EA, Chapman ER (2004) Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc Natl Acad Sci USA, 101(41):14701–4704.
17. Ruig DR, Dunning FM, Piazza TM, Moltes BE, Adler M, et al. (2011) Detection of six serotypes of botulinum neurotoxin using fluorogenic reporters. Anal Biochem. 412(2):200–9.
18. Joshi SG (2012) Detection of biologically active botulinum neurotoxin--A in serum using high-throughput FRET-assay. J Pharmacol Toxicol Methods 65(1):8–12.
19. Hallis B, James BA, Shone CC (1996) Development of novel assays for Clostridium botulinum type A and B neurotoxins based on their endopeptidase activities. J. Immunol. Methods 180: 181–191.
20. Ekong TA, Feavers IM, Sarsfield D (1997) Reombinant SNAP25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. Microbiology 143, 3337–47.
21. Gaines Das RE, Heath AB, Martin H, Sesardic D (1999) Validation of in vitro assays for botulinum toxin: a case study. Dev. Biol. Stand. 101: 267–76.

22. Schmidt JJ, Stafford RG, Millard CB (2001) High-throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F. Anal Biochem. 296(1): 130–7

23. Shone C, Ferreira J, Boyer A, Cirino N, Egan C, et al. (2006). The 5th International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Neurotoxins. Workshop review: assays and detection. Neurotox. Res. 9: 205–16.

24. Jones RG, Ochiai M, Liu Y, Ekong T, Sesardic D (2008) Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. Journal of Immunological Methods 329: 92–101.

25. Wang HH, Reling S, Lindo P, Singh BR (2010) Endopeptidase activities of botulinum neurotoxin type B complex, holotoxin, and light chain. Appl Environ Microbiol. 76(19):6658–63.

26. Jones RG, Liu Y, Sesardic D (2009) New highly specific botulinum type C1 endopeptidase immunoassays utilising SNAP25 or Syntaxin substrates. J Immunol Methods. 345(1):21–7.

27. Schmidt JJ, Bostian KA (1995) Proteolysis of synthetic peptides by type A botulinum neurotoxin. J. Prot. Chem. 14:703–708.

28. Tse CK, Dolly JO, Hambleton P, Wray D, Melling J (1982) Preparation and characterisation of homogeneous neurotoxin type A from Clostridium botulinum. Its inhibitory action on neuronal release of acetylcholine in the absence and presence of beta-bungarotoxin. Eur J Biochem. 122(3): 493–500.

29. Kovacs-Nolan J, Mine Y (2004) Avian egg antibodies: basic and potential applications. Avian Poult. Biol. Rev. 15(1): 23–46.

30. Wang Q, Cai K, Hou XJ, Tu W, Xiao L, et al. (2010) Passive protection of purified Yolk Immunoglobulin administered against Shiga toxin 1 in mouse models. Can J Microbiol, 56(12):1003–1010.